Project Grant R01AI198262
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $727K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $160,609 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research targeting post-fusion influenza hemagglutinin to develop a more effective flu vaccine. The project runs through May 31, 2028, with place of performance in Boston, Massachusetts. The award is structured as a Project Grant, a competitive...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $267,000 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research decoding gasdermin D (GSDMD) pore clustering as a regulatory checkpoint controlling pyroptosis, a lytic and inflammatory form...
- The National Institute of Allergy and Infectious Diseases awarded $864,475 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic structural and functional research on coronavirus spike proteins in membrane environments. The funded work examines distinct conformational states of membrane-bound spike proteins reconstituted in lipid bilayers, with focus...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $445,000 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel immunoregulatory mechanisms that modulate myeloid trained immunity following transplantation. The research examines innate immune responses in transplant recipients, focusing on how monocytes expressing neuropilin 2 (NRP2) can...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital) on July 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Overcoming Obstacles in Structural Elucidation of B Cell Antigen Receptor Assembly and Lateral Interaction," will be conducted through June 30, 2027, in Massachusetts. The research...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $267,000 on July 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory B cell function in transplant alloimmunity. The project examines whether neuropilin-2 (NRP2)-expressing B cell subsets promote immunoregulation and suppress CD4+ T effector cell activation in the context of organ transplant...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $889,519 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop multi-biologic, adeno-associated virus (AAV)-deliverable HIV-1 therapeutics for potential functional cure applications. The funded research advances AAV-vector delivery of broadly neutralizing antibodies and ECD4-IG, a potency and half-life...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital (The Children's Hospital Corporation) $124,992 on May 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant K99AI199041. The award funds research dissecting the priming and activation mechanisms of the NLRP3 inflammasome in sterile inflammatory diseases, particularly atherosclerosis and cryopyrin-associated periodic syndromes (CAPS). In the K99 phase, the...
- The National Institute of Allergy and Infectious Diseases awarded the Children's Hospital Corporation $278,868 on January 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to validate viral metagenomic sequencing of dust samples from elementary schools for early detection of emerging viral strains. The project conducts metagenomic profiling of 571 dust samples longitudinally collected from 209 classrooms across 41 schools between 2015 and 2019 as an ancillary...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation (Boston Children's Hospital) $794,886 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of endogenous chimeric mRNA-encoded gasdermin D fusion proteins in pyroptosis and innate immunity. The research employs long-read direct RNA sequencing to identify and characterize chimeric mRNA (chRNA) species in mammalian cells, with focus...